MMV’s Drug Discovery Portfolio

Curing Malaria Together  www.mmv.org

Medicines for Malaria Venture
Introduction

Win Gutteridge
Chair, MMV’s Expert Scientific Advisory Committee (ESAC)
MMV’s Driver

- Declaration in Seattle on 17 October 2007 by Bill and Melinda Gates (BMGF) and endorsed by Margaret Chan (DG WHO) that it was time to have another go at malaria:

ERADICATION
MMV’s Product R&D Goals

• Short term:
  • Complete the development of its 4 ACTs for the treatment of *falciparum* malaria and extend their use to *vivax* malaria

• Medium term:
  • Develop treatments non-po patients with severe *falciparum* malaria, for the radical cure of *vivax* malaria and for the intermittent treatment of pregnant women and infants

• Long term:
  • Discover and develop non-artemisinin-based combination therapies (NACTs) to replace the ACTs
* Portfolio has potentially 27 discovery projects and 8 development projects
**MMV Portfolio 2007**

<table>
<thead>
<tr>
<th>Exploratory</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Development</th>
<th>Regulatory</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lead Identification</strong></td>
<td><strong>Lead Optimization</strong></td>
<td><strong>Phase I</strong></td>
<td><strong>Phase II</strong></td>
<td><strong>Phase III</strong></td>
</tr>
<tr>
<td>PSAC antagonists</td>
<td>Novel Liver Stage Antimalarials</td>
<td>OZ Next Generation</td>
<td>Tafenoquine plus</td>
<td>Chlorproguanil - dapsone - artesunate (CDA) Dacart™</td>
</tr>
<tr>
<td>Pf enoyl-ACP reductase (Fab I)</td>
<td>Immucillins</td>
<td>4(1H)-pyridones Back ups</td>
<td>Dispersible Coartem™</td>
<td>Dihydroartemisinin-piperaquine Euratesim™</td>
</tr>
<tr>
<td>TDR22093 Series</td>
<td>Falcipain (cysteine protease)</td>
<td>4(1H)-pyridone</td>
<td>Pyronaridine – Artesunate Pyramax™</td>
<td></td>
</tr>
<tr>
<td>Novartis Institute for Tropical Diseases Collaboration: 9 active projects</td>
<td>Novel Macrolides</td>
<td>MK-4815</td>
<td>Artesunate parenteral</td>
<td></td>
</tr>
<tr>
<td>Broad Institute of MIT/Harvard – Genzyme Collaboration: 5 active projects</td>
<td>Dihydrofolate reductase (DHFR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natural Products Whole-Cell HTS</td>
<td>Dihydroorototate dehydrogenase inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natural Products as New Prototypes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Portfolio has potentially 27 discovery projects and 8 development projects*
Programme

- PSAC antagonists as lead compounds for antimalarial drug development: Sanjay Desai
- Novel inhibitors of DHFR: Yongyuth Yuthavong
- Next generation synthetic peroxide antimalarials: Sue Charman
- 4-Pyridones as putative antimalarials: Domingo Gargallo
- Concluding remarks: Win Gutteridge
Programme

• PSAC antagonists as lead compounds for antimalarial drug development: Sanjay Desai

• Novel inhibitors of DHFR: Yongyuth Yuthavong

• Second generation synthetic peroxide antimalarials: Sue Charman

• 4-Pyridones as putative antimalarials: Domingo Gargallo

• Concluding remarks: Win Gutteridge

MMV’s Sixth Call
For LOIs
Dec 07
MMV’s Drug Discovery Portfolio

Curing Malaria Together  www.mmv.org

Medicines for Malaria Venture